financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
Mar 4, 2024 11:01 PM

01:00 PM EST, 02/29/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target to $71 from $47 on a P/S of 7.5x, above its three-year average on good sales execution and a favorable deal pipeline, using our next-12-month sales estimate of $2.3B. We lift our FY 24 EPS view to $1.07 from $0.95 and FY 25's to $1.33 from $1.21. NTNX posted Q2 sales of $565.2M, above consensus by $14.8M, while non-GAAP EPS of $0.46 beat by $0.17. Revenue rose 16.2% Y/Y from solid Subscription revenue growth (+18% Y/Y) as ACV billings outperformed, up 23% Y/Y, from higher-than-anticipated renewals. We note NTNX's commentary around a continued uncertain macro environment, and longer average sales cycles, which likely impacted contract duration of 2.8 years in Q2, lower than Q1. However, these results reflect the firm's strong execution in securing and keeping pace with renewals and expansion deals, as well as maintaining healthy pricing levels in spite of these challenges. Its upbeat guidance and a higher mix of large deals in the pipeline further support our positive view of the business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Keeps Buy Opinion On Shares Of Boston Scientific Corporation
Research Alert: CFRA Keeps Buy Opinion On Shares Of Boston Scientific Corporation
Mar 11, 2024
01:05 PM EDT, 03/11/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target price on shares of Boston Scientific ( BSX ) to $75 from $71, 29.3x our 2025 EPS estimate, a premium to BSX's historical forward average, justified...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Consolidated Communications Holdings
Research Alert: CFRA Maintains Hold Opinion On Shares Of Consolidated Communications Holdings
Mar 11, 2024
12:10 PM EDT, 03/11/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $5, applying an EV/sales multiple of 2.8x to our 2024 estimate, in line with its 10-year historical average multiple at 2.8x, reflecting our...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Docusign, Inc.
Research Alert: CFRA Maintains Hold Opinion On Shares Of Docusign, Inc.
Mar 11, 2024
10:45 AM EDT, 03/11/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $5 to $65, applying an EV/sales multiple of 4.2x to our FY 2025 (Jan.) estimate, a slight premium to peers, reflecting its dominant...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Ciena Corporation
Research Alert: CFRA Maintains Hold Opinion On Shares Of Ciena Corporation
Mar 11, 2024
10:50 AM EDT, 03/11/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $5 to $55, 24.0x our FY 2024 (Oct.) EPS estimate, a discount to its three-year historical average P/E multiple of 28.1x, reflecting our...
Copyright 2023-2026 - www.financetom.com All Rights Reserved